The effect of rosuvastatin in multiple sclerosis

Phase 2

Recruiting

• Conditions: Multiple sclerosis.; Multiple sclerosis

• Registration Number: IRCT20210211050323N2
• Lead Sponsor: Hamedan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 1 November 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Definitive diagnosis of multiple sclerosis by a neurologist
Radiographic findings of magnetic resonance imaging ( MRI ) consistent with the clinical diagnosis of multiple sclerosis
No other concomitant inflammatory disease
Bad cholesterol levels (low-density lipoprotein) less than 130 mg / dL
No pregnancy and lactation
Do not take medications other than standard treatments for multiple sclerosis that alter the levels of the factors under consideration.
Do not use any combination with antioxidant effects in the past month.

Exclusion Criteria

Existing evidence based on increased patient disability
Consumption of any combination or drug with antioxidant effects except prescription drugs
Existence of any cognitive or behavioral disorders that lead to the patient not cooperating.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Sirtuin1 gene expression. Timepoint: Before the intervention and 3 months after the start of the intervention. Method of measurement: Laboratory.

Secondary Outcome Measures

Name	Time	Method
Expanded Disability Status Scale (EDSS ) score. Timepoint: Before the intervention and 3 months after the start of the intervention. Method of measurement: Expanded Disability Status Scale (EDSS) questionnaire.